Search results
Results From The WOW.Com Content Network
Alembic Pharmaceuticals. Alembic Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company headquartered in Vadodara. [2] It is involved in the manufacture of pharmaceutical products, pharmaceutical substances and intermediates. It is also termed to be a market leader in macrolides segment of anti-infective drugs in India.
In February 2020, American Health Packaging recalled some lots of ranitidine tablets manufactured by Amneal Pharmaceuticals. [ 120 ] In April 2020, the FDA requested a manufacturer's market withdrawal of ranitidine, [ 19 ] [ 121 ] meaning that ranitidine products would not be available for prescription or over-the-counter sale in the US.
Mimi’s Products ground cinnamon: 2.03 ppm. ShopRite Bowl & Basket ground cinnamon: 1.82 ppm. Rani Brand ground cinnamon: 1.39 ppm. Zara Foods cinnamon powder: 1.27 ppm. Three Rivers cinnamon ...
Alembic Group is an Indian conglomerate headquartered in Vadodara.It was founded in 1907 [5] and was initially known as Alembic Chemical Works Company Ltd. The company was founded by Prof. T.K. Gajjar, Prof. A.S. Kotibhasker and B.D. Amin. [6] It is one of the oldest industrial houses in India and has a diversified portfolio of business. [2]
Pharmaceutical recalls skyrocketed to 517 events in 2023 compared to 363 the year before, a 42.4% increase, according to Sedgwick’s State of the Nation 2024 Product Safety and Recall report ...
India's Alembic Pharmaceuticals on Tuesday reported second-quarter profit roughly in line with estimates, as higher sales in its domestic and overseas markets offset a jump in expenses. The ...
Website. www.intaspharma.com. Intas Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. [2] It is a producer of generic therapeutic drugs and engaged in contract clinical research and manufacturing. [3] It has 22 manufacturing plants, 17 in India and the rest in Greece, United Kingdom and Mexico ...
UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...